Finanzen von Terns Pharmaceuticals Inc (TERN)TERNTerns Pharmaceuticals Inc

Evaluating the bottom line, Terns Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -14.23%, provide a clear picture of how effectively TERN converts its operational activities into shareholder value.

In the context of the broader market, TERN competes directly with industry leaders such as APGE and COGT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TERN's gross margin of N/A stands against APGE's N/A and COGT's N/A. Such benchmarking helps identify whether Terns Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

In 2025/Q4, the company reported no revenue growth (0% YoY), and net income improved slightly but remains negative at -$23.57M. EPS also showed no growth, remaining at -0.24.